DK3612208T5 - Coversin til behandlingen af autoimmune sygdomme med blisterdannelse - Google Patents
Coversin til behandlingen af autoimmune sygdomme med blisterdannelse Download PDFInfo
- Publication number
- DK3612208T5 DK3612208T5 DK18726731.5T DK18726731T DK3612208T5 DK 3612208 T5 DK3612208 T5 DK 3612208T5 DK 18726731 T DK18726731 T DK 18726731T DK 3612208 T5 DK3612208 T5 DK 3612208T5
- Authority
- DK
- Denmark
- Prior art keywords
- coversin
- treatment
- autoimmune diseases
- blister formation
- blister
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Transplantation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1706406.4A GB201706406D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GBGB1706404.9A GB201706404D0 (en) | 2017-04-21 | 2017-04-21 | Method of treatment |
| GBGB1706452.8A GB201706452D0 (en) | 2017-04-24 | 2017-04-24 | Method of treatment |
| PCT/EP2018/060241 WO2018193122A1 (en) | 2017-04-21 | 2018-04-20 | Coversin for the treatment of autoimmune blistering diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3612208T3 DK3612208T3 (da) | 2023-05-08 |
| DK3612208T5 true DK3612208T5 (da) | 2024-09-02 |
Family
ID=62235916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18726731.5T DK3612208T5 (da) | 2017-04-21 | 2018-04-20 | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11730792B2 (enExample) |
| EP (2) | EP4275696A1 (enExample) |
| JP (2) | JP7209637B2 (enExample) |
| KR (1) | KR102656199B1 (enExample) |
| CN (1) | CN110896606B (enExample) |
| AU (1) | AU2018253962B2 (enExample) |
| CA (1) | CA3059657A1 (enExample) |
| DK (1) | DK3612208T5 (enExample) |
| ES (1) | ES2945433T3 (enExample) |
| IL (1) | IL269895B2 (enExample) |
| PL (1) | PL3612208T3 (enExample) |
| WO (1) | WO2018193122A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN110831617A (zh) * | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
| GB201706406D0 (en) | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP7209637B2 (ja) | 2017-04-21 | 2023-01-20 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 自己免疫性水疱症の治療のためのコバーシン |
| JP7629394B2 (ja) * | 2018-09-10 | 2025-02-13 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | リウマチ性疾患の治療に使用するためのコバーシン |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP2023503776A (ja) * | 2019-09-27 | 2023-02-01 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法 |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US7884188B2 (en) | 2003-06-02 | 2011-02-08 | Varleigh Immuno Pharmaceuticals (Vip) Ltd | Complement inhibitors |
| EP1739078A1 (de) * | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| WO2007095230A2 (en) | 2006-02-13 | 2007-08-23 | The Trustees Of The University Of Pennsylvania | TREATMENT OF AUTOIMMUNE BLISTERING DISEASE USING ANTI-IgE ANTIBODY |
| EP2061501B1 (en) * | 2006-09-08 | 2015-04-08 | Volution Immuno Pharmaceuticals SA | Method of treating respiratory disorders |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| WO2008113834A2 (en) | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| US8563521B2 (en) * | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| EP2331564A4 (en) * | 2008-10-06 | 2013-02-20 | Carolus Therapeutics Inc | PROCESS FOR TREATMENT OF IGNITION |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| NZ597259A (en) | 2009-06-23 | 2014-04-30 | Alexion Pharma Inc | Bispecific antibodies that bind to complement proteins |
| US9290736B2 (en) * | 2009-11-04 | 2016-03-22 | Case Western Reserve University | Compositions and methods of treating T cell mediated disorder |
| CA2785612C (en) | 2010-01-08 | 2019-09-10 | Varleigh Immuno Pharmaceuticals (Vip) Ltd. | Ev576 for use in the treatment of viral infections of the respiratory tract |
| CA2840270C (en) | 2011-06-22 | 2023-09-26 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| TW201418707A (zh) | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| JP6505079B2 (ja) | 2013-03-29 | 2019-04-24 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法 |
| GB201410031D0 (en) * | 2014-06-05 | 2014-07-16 | Isis Innovation | Polypeptides and uses thereof |
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2016198133A1 (en) | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| US20160168237A1 (en) * | 2014-12-12 | 2016-06-16 | Alexion Pharmaceuticals, Inc. | Method for treating a complement mediated disorder caused by an infectious agent in a patient |
| SMT202100688T1 (it) * | 2015-01-28 | 2022-01-10 | Ra Pharmaceuticals Inc | Modulatori di attività del complemento |
| WO2016200627A1 (en) * | 2015-06-09 | 2016-12-15 | Children's Hospital Medical Center | Dosing algorithm for complement inhibitor |
| EP3307316A1 (en) * | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
| EP3328885A1 (en) * | 2015-09-11 | 2018-06-06 | Bruce Andrien | Recombinant glycosylated eculizumab and eculizumab variants |
| JP7209637B2 (ja) | 2017-04-21 | 2023-01-20 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 自己免疫性水疱症の治療のためのコバーシン |
| GB201706406D0 (en) * | 2017-04-21 | 2017-06-07 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CN110831617A (zh) | 2017-04-21 | 2020-02-21 | 沃卢申伊缪诺制药公司 | 用于治疗瘢痕性眼部发炎性病症的Coversin |
-
2018
- 2018-04-20 JP JP2019556794A patent/JP7209637B2/ja active Active
- 2018-04-20 EP EP23166056.4A patent/EP4275696A1/en not_active Withdrawn
- 2018-04-20 EP EP18726731.5A patent/EP3612208B1/en active Active
- 2018-04-20 ES ES18726731T patent/ES2945433T3/es active Active
- 2018-04-20 PL PL18726731.5T patent/PL3612208T3/pl unknown
- 2018-04-20 DK DK18726731.5T patent/DK3612208T5/da active
- 2018-04-20 US US16/603,352 patent/US11730792B2/en active Active
- 2018-04-20 KR KR1020197031711A patent/KR102656199B1/ko active Active
- 2018-04-20 CA CA3059657A patent/CA3059657A1/en active Pending
- 2018-04-20 WO PCT/EP2018/060241 patent/WO2018193122A1/en not_active Ceased
- 2018-04-20 CN CN201880041710.5A patent/CN110896606B/zh active Active
- 2018-04-20 IL IL269895A patent/IL269895B2/en unknown
- 2018-04-20 AU AU2018253962A patent/AU2018253962B2/en active Active
-
2023
- 2023-01-10 JP JP2023001554A patent/JP7600278B2/ja active Active
- 2023-06-09 US US18/332,191 patent/US20240009270A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PL3612208T3 (pl) | 2023-07-24 |
| JP7600278B2 (ja) | 2024-12-16 |
| JP2023040169A (ja) | 2023-03-22 |
| EP3612208B1 (en) | 2023-04-05 |
| JP7209637B2 (ja) | 2023-01-20 |
| EP4275696A1 (en) | 2023-11-15 |
| CN110896606B (zh) | 2024-07-16 |
| CA3059657A1 (en) | 2018-10-25 |
| EP3612208A1 (en) | 2020-02-26 |
| AU2018253962A1 (en) | 2019-10-31 |
| DK3612208T3 (da) | 2023-05-08 |
| KR20190139233A (ko) | 2019-12-17 |
| IL269895B2 (en) | 2024-06-01 |
| KR102656199B1 (ko) | 2024-04-09 |
| ES2945433T3 (es) | 2023-07-03 |
| US20200113971A1 (en) | 2020-04-16 |
| WO2018193122A1 (en) | 2018-10-25 |
| IL269895A (enExample) | 2019-12-31 |
| JP2020517627A (ja) | 2020-06-18 |
| US11730792B2 (en) | 2023-08-22 |
| US20240009270A1 (en) | 2024-01-11 |
| CN110896606A (zh) | 2020-03-20 |
| IL269895B1 (en) | 2024-02-01 |
| AU2018253962B2 (en) | 2024-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3501542T3 (da) | Esketamin til behandling af depression | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| DK3728271T3 (da) | Makrocykliske forbindelser til behandling af sygdomme | |
| DK3609529T3 (da) | Rna til behandling af autoimmune sygdomme | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3612208T3 (da) | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse | |
| DK3326641T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3244948T3 (da) | Bestemmelse af medikamentdosis | |
| DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3865484T3 (da) | Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme | |
| DK3498278T3 (da) | Forbindelser til behandling af sygdomme relateret til DUX4-ekspression | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3250600T3 (da) | Behandling af autoimmune lidelser med cd154-antistoffer | |
| DK3210973T3 (da) | Heteroarylforbindelser til behandling af oftalmiske sygdomme | |
| DK3578562T3 (da) | L-valinatamidbenzoxaborolderivater til behandling af parasitiske sygdomme | |
| DK3585808T3 (da) | Modificerede serpiner til behandlingen af bradykinin formidlet sygdom | |
| DK3506956T3 (da) | Lægemiddel, særlig til behandling af fistler | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3373931T3 (da) | Heterocykliske forbindelser til behandling af sygdom | |
| DK3484475T3 (da) | 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom |